MDRO's (MRSA, VRE)
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
 | |  | |  | |  | |  |
| Resources |
PREVENTION AND CONTROL OF MULTI-DRUG RESISTANT ORGANISMS:
Multi-drug resistant organisms (MDRO’s) are a major concern for most hospitals. They
burden on health care resources.
• Methicillin-resistant Staphylococcus aureus (MRSA)
According to CDC data, the proportion of antimicrobial resistant Staphylococcus aureus
infections has been growing significantly over the past few decades. In 1974, MRSA
infections accounted for just two percent of the total number of S. aureus infections; in
1995 this had risen to 22%; and by 2006 over 75% of infections showed resistance in
the US.
• Extended spectrum B-lactamase-producing Enterobacteria (ESBL)
Microbial resistance through extended-spectrum B-lactamase was first reported in the
1980s, soon after the introduction of 3rd generation cephalosporins in clinical practice.
Today, ESBL-producing Enterobacteria is recognized as nosocomial pathogens of
major importance.
• Vancomycin-resistant enterococci (VRE)
Enterococci with acquired vancomycin resistance are responsible for 1 in 3 infections in
US intensive care units; and, VRE outbreaks more than doubled in Europe between
2001 and 2005. Transfer of vancomycin resistance from enterococci to staphylococci
(VRSA) is a major threat for the healthcare community.
Multi-drug resistant organisms (MDRO’s) are a major concern for most hospitals. They
burden on health care resources.
• Methicillin-resistant Staphylococcus aureus (MRSA)
According to CDC data, the proportion of antimicrobial resistant Staphylococcus aureus
infections has been growing significantly over the past few decades. In 1974, MRSA
infections accounted for just two percent of the total number of S. aureus infections; in
1995 this had risen to 22%; and by 2006 over 75% of infections showed resistance in
the US.
• Extended spectrum B-lactamase-producing Enterobacteria (ESBL)
Microbial resistance through extended-spectrum B-lactamase was first reported in the
1980s, soon after the introduction of 3rd generation cephalosporins in clinical practice.
Today, ESBL-producing Enterobacteria is recognized as nosocomial pathogens of
major importance.
• Vancomycin-resistant enterococci (VRE)
Enterococci with acquired vancomycin resistance are responsible for 1 in 3 infections in
US intensive care units; and, VRE outbreaks more than doubled in Europe between
2001 and 2005. Transfer of vancomycin resistance from enterococci to staphylococci
(VRSA) is a major threat for the healthcare community.
Steiros LLC Infection Control Consultants
6475 E. Pacific Coast Hwy, Suite 450
Long Beach, California 90803
Serving the USA
US Patent Pending
6475 E. Pacific Coast Hwy, Suite 450
Long Beach, California 90803
Serving the USA
US Patent Pending
Steiros Infection Control
| The Future of Epidemiology |
| www.Steiros.com www.Steiros.net email: steirosinc@yahoo.com |